-
Seribantumab (INN;
development code MM-121) is a
monoclonal antibody designed for the
treatment of cancer. It
binds to
extracellular domain of HER3 blocking...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
- (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding EGF-like growth...
